{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CXL&page=2",
    "query": {
      "intervention": "CXL",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CXL&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-14T04:04:08.164Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01398852",
      "title": "Safety and Effectiveness Study of the VEGA UV-A System for Cross-linking in Eyes With Keratoconus and Ectasia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Keratoconus and Ectasia"
      ],
      "interventions": [
        {
          "name": "Riboflavin",
          "type": "DRUG"
        },
        {
          "name": "VEGA UV-A Illumination System",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Topcon Medical Systems, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 500,
      "start_date": "2010-12",
      "completion_date": "2012-07",
      "has_results": true,
      "last_update_posted_date": "2022-06-29",
      "last_synced_at": "2026-09-14T04:04:08.164Z",
      "location_count": 13,
      "location_summary": "Phoenix, Arizona • Atlanta, Georgia • Boston, Massachusetts + 7 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Bloomington",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01398852"
    },
    {
      "nct_id": "NCT01624246",
      "title": "Pharmacokinetic Study of Ceftaroline Fosamil/Avibactam in Adults With Augmented Renal Clearance",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Augmented Renal Clearance (ARC)",
        "Systemic Inflammatory Response Syndrome (SIRS)"
      ],
      "interventions": [
        {
          "name": "Ceftaroline fosamil/Avibactam (CXL)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Forest Laboratories",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 12,
      "start_date": "2012-05",
      "completion_date": "2013-03",
      "has_results": false,
      "last_update_posted_date": "2017-04-07",
      "last_synced_at": "2026-09-14T04:04:08.164Z",
      "location_count": 19,
      "location_summary": "Fresno, California • Los Angeles, California • San Diego, California + 16 more",
      "locations": [
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01624246"
    },
    {
      "nct_id": "NCT07135167",
      "title": "Compassionate Use Study of Epi-ON Corneal Collagen Crosslinking Performed Using UVA Exposure on Eyes With Ectatic Corneal Diseases for Subjects With Down Syndrome",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Down Syndrome (DS)",
        "Keratoconus",
        "Pellucid Marginal Degeneration",
        "Forme Fruste Keratoconus (FFK)"
      ],
      "interventions": [
        {
          "name": "Epi-ON corneal cross-linking (CXL)",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Woolfson Eye Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "8 Years and older"
      },
      "enrollment_count": 225,
      "start_date": "2025-08-01",
      "completion_date": "2028-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-02-02",
      "last_synced_at": "2026-09-14T04:04:08.164Z",
      "location_count": 12,
      "location_summary": "Atlanta, Georgia • Canton, Georgia • Cumming, Georgia + 8 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Canton",
          "state": "Georgia"
        },
        {
          "city": "Cumming",
          "state": "Georgia"
        },
        {
          "city": "Douglasville",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07135167"
    },
    {
      "nct_id": "NCT03319082",
      "title": "Observational Registry to Assess the Durability of Effect of CXL in Patients With Corneal Ectasia After Refractive Surgery",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Corneal Ectasia"
      ],
      "interventions": [
        {
          "name": "Corneal Collagen Cross-linking",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Glaukos Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2017-10-04",
      "completion_date": "2026-02",
      "has_results": false,
      "last_update_posted_date": "2024-02-23",
      "last_synced_at": "2026-09-14T04:04:08.164Z",
      "location_count": 11,
      "location_summary": "Palo Alto, California • Bloomington, Minnesota • Bozeman, Montana + 8 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Bloomington",
          "state": "Minnesota"
        },
        {
          "city": "Bozeman",
          "state": "Montana"
        },
        {
          "city": "West Fargo",
          "state": "North Dakota"
        },
        {
          "city": "Westerville",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03319082"
    },
    {
      "nct_id": "NCT06235567",
      "title": "Dextenza Versus Topical Steroid Eye Drops for Postoperative Management Following Corneal Crosslinking",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Keratoconus"
      ],
      "interventions": [
        {
          "name": "Dextenza 0.4Mg Ophthalmic Insert",
          "type": "DRUG"
        },
        {
          "name": "topical prednisolone acetate 1% (PredForte) eye drops",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Maanasa Indaram, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "13 Years to 64 Years"
      },
      "enrollment_count": 20,
      "start_date": "2025-04-11",
      "completion_date": "2027-07",
      "has_results": false,
      "last_update_posted_date": "2026-09-11",
      "last_synced_at": "2026-09-14T04:04:08.164Z",
      "location_count": 3,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06235567"
    },
    {
      "nct_id": "NCT04177082",
      "title": "Safety and Effectiveness of the PXL-Platinum 330 System for CXL Using Riboflavin Solution",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Keratoconus",
        "Pellucid Marginal Corneal Degeneration",
        "Corneal Degeneration",
        "Corneal Ectasia"
      ],
      "interventions": [
        {
          "name": "PXL-330 Platinum device for crosslinking with Peschke riboflavin solution",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Cornea Associates of Texas",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "8 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2020-01-10",
      "completion_date": "2022-05-05",
      "has_results": false,
      "last_update_posted_date": "2022-10-19",
      "last_synced_at": "2026-09-14T04:04:08.164Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04177082"
    },
    {
      "nct_id": "NCT01708538",
      "title": "The Effects of Corneal Collagen Cross-linking",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Corneal Ectasia Disorders Including Keratoconus"
      ],
      "interventions": [
        {
          "name": "CXL",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rush Eye Associates",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "10 Years to 70 Years"
      },
      "enrollment_count": 30,
      "start_date": "2012-10",
      "completion_date": "2024-10",
      "has_results": false,
      "last_update_posted_date": "2022-10-26",
      "last_synced_at": "2026-09-14T04:04:08.164Z",
      "location_count": 1,
      "location_summary": "Amarillo, Texas",
      "locations": [
        {
          "city": "Amarillo",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01708538"
    },
    {
      "nct_id": "NCT05255107",
      "title": "Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Previously Untreated Corneal Ulcers",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Keratitis",
        "Corneal Ulcer"
      ],
      "interventions": [
        {
          "name": "Standard of Care Therapy + CXL + Riboflavin 0.23% L Solution",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Standard of Care Therapy + Sham CXL + Artificial Tears",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "OTHER"
      ],
      "sponsor": "Peschke GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 468,
      "start_date": "2022-03-14",
      "completion_date": "2024-02-24",
      "has_results": false,
      "last_update_posted_date": "2022-10-28",
      "last_synced_at": "2026-09-14T04:04:08.164Z",
      "location_count": 12,
      "location_summary": "Littleton, Colorado • Fort Myers, Florida • Tampa, Florida + 9 more",
      "locations": [
        {
          "city": "Littleton",
          "state": "Colorado"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Teaneck",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05255107"
    },
    {
      "nct_id": "NCT05136924",
      "title": "IIT Assessing OC-01Nasal Spray on Symptoms of DED Following CXL",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dry Eye Disease"
      ],
      "interventions": [
        {
          "name": "OC-01 (varenicline 1.2mg/ml) nasal spray vs Placebo",
          "type": "DRUG"
        },
        {
          "name": "Placebo (vehicle) nasal spray",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Vance Thompson Vision - MT",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2021-12-01",
      "completion_date": "2022-06-01",
      "has_results": false,
      "last_update_posted_date": "2021-11-30",
      "last_synced_at": "2026-09-14T04:04:08.164Z",
      "location_count": 1,
      "location_summary": "Bozeman, Montana",
      "locations": [
        {
          "city": "Bozeman",
          "state": "Montana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05136924"
    },
    {
      "nct_id": "NCT05255016",
      "title": "Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Refractory Corneal Ulcers",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Keratitis",
        "Corneal Ulcer"
      ],
      "interventions": [
        {
          "name": "PXL Platinum 330 system + Riboflavin 0.25% TE Solution",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Sham CXL + Artificial Tears",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "OTHER"
      ],
      "sponsor": "Peschke GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 488,
      "start_date": "2022-03-14",
      "completion_date": "2024-02-24",
      "has_results": false,
      "last_update_posted_date": "2022-10-28",
      "last_synced_at": "2026-09-14T04:04:08.164Z",
      "location_count": 12,
      "location_summary": "Littleton, Colorado • Fort Myers, Florida • Tampa, Florida + 9 more",
      "locations": [
        {
          "city": "Littleton",
          "state": "Colorado"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Teaneck",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05255016"
    }
  ]
}